27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Last month, Biogen Inc (NASDAQ:BIIB) halted Phase 3 trials for aducanumab in March based on results of a futility analysis conducted by an independent data monitoring committee.
While the remaining business is not busted, it does seem fragile, with the company facing headwinds in both multiple sclerosis and spinal muscular atrophy, according to Raymond James.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Analyst
Raymond James’ Steven Seedhouse resumed coverage of Biogen with a Market Perform rating.
The Thesis
Biogen’s MS franchise is facing several risks, including new launches like Celgene Corporation (NASDAQ:CELG)'s ozanimod; Novartis AG (NYSE:NVS)'s Mayzent; Merck's Mavenclad; a pending IPR decision on Biogen's Tecfidera IP and pricing that's subject to intense political pressure in the U.S., Seedhouse said in a Tuesday note.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
In the spinal muscular atrophy arena, the annual sales of Spinraza have already peaked, with market share remaining flat and the dosing mix shifting from loading to maintenance, the analyst said. The latter signifies a massive cut in the gross price, from $750,000 to $375,000 per year per patient, he said.
Spinraza sales will be further impacted by the launches of Zolgesma by Novartis and risdiplam by Roche Holding and PTC Therapeutics, Inc. (NASDAQ:PTCT), Seedhouse said.
Biogen seems to understand the challenges ahead “to retool the business outlook and growth prospects in a stepwise manner,” the analyst said.
Price Action
Biogen shares were trading down 0.13 percent at $237.28 at the time of publication Wednesday.
Related Links:
6 Gene Therapy M&A Targets On The Radar
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.